Synerkine Pharma is pioneering a novel class of therapeutics known as "Synerkines," which leverage the unique properties of receptor clustering to enhance the therapeutic effects of cytokines. By heterodimerizing receptor chains, Synerkines facilitate the clustering of receptor complexes that typically do not interact closely. This innovative mechanism leads to distinct gene transcription patterns and a significantly amplified biological response compared to the effects achieved through the co-administration of individual cytokines. This approach aims to improve treatment outcomes for various conditions, particularly chronic pain syndromes.

The company is currently focused on developing two main therapeutic candidates: SK-01 and SK-02. SK-01 targets Complex Regional Pain Syndrome (CRPS) and has received European Orphan Drug Designation, highlighting its potential to address a significant unmet medical need in chronic pain management. Meanwhile, SK-02 is designed to combat chemotherapy-induced peripheral neuropathy (CIPN) by combining the effects of interleukin-4 (IL-4) and interleukin-13 (IL-13). Initial studies suggest that SK-02 not only provides analgesic benefits but may also offer neuroprotective effects, positioning it as a promising solution for alleviating the debilitating symptoms associated with CIPN.

Netherlands

Synerkine Pharma B.V. focuses on development of novel fusion proteins, called Synerkines, that combine the immunoregulatory activity of different cytokines. These fusion proteins have unique benefits over the individual cytokines and modulate a broad number of targets, including key elements in the pain pathway. This provides treatment options for chronic pain conditions with a clearly differentiated mechanism of action over current analgesic drugs and holds tremendous therapeutic and commercial potential. Synerkine Pharma B.V. was founded in 2018 as a spin-off of the University Medical Center Utrecht (UMCU), the Netherlands.

Synerkine Pharma

Company Details